ES2059370T3 - Un virus herpes simplex recombinante, vacunas y metodos. - Google Patents

Un virus herpes simplex recombinante, vacunas y metodos.

Info

Publication number
ES2059370T3
ES2059370T3 ES87303512T ES87303512T ES2059370T3 ES 2059370 T3 ES2059370 T3 ES 2059370T3 ES 87303512 T ES87303512 T ES 87303512T ES 87303512 T ES87303512 T ES 87303512T ES 2059370 T3 ES2059370 T3 ES 2059370T3
Authority
ES
Spain
Prior art keywords
vaccines
hsv
methods
genome
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87303512T
Other languages
English (en)
Inventor
Bernard Roizman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp filed Critical Arch Development Corp
Application granted granted Critical
Publication of ES2059370T3 publication Critical patent/ES2059370T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTAN VIRUS DE HERPES RECOMBINANTES UTILES COMO INGREDIENTES EFECTIVOS EN VACUNAS CONTRA LOS VIRULENTOS HSV-1 Y HSV-2. METODOS DE PREPARACION DE LOS VIRUS RECOMBINANTES, VACUNAS QUE CONTIENEN LOS VIRUS Y METODOS DE INMUNIZACION POR INOCULACION CON LAS VACUNAS. LOS GENOMAS DE LOS VIRUS RECOMBINANTES COMPRENDEN CADA UNO UN MUTANTE DEL GENOMA HSV-1 A PARTIR DEL CUAL SE REPRIME UNA PORCION RESPONSABLE DE LA NEUROVIRULENCIA PERO NO ESENCIAL PARA EL CRECIMIENTO. UN GEN DEL GENOMA HSV-2 RESPONSABLE DE LA CODIFICACION DE UNA GLICOPROTEPINA INDUCTORA DE INMUNIDAD SE INSERTA EN EL GENOMA MUTANTE ENTRE LOS PUNTOS FINALES DE LA SUPRESION.
ES87303512T 1986-04-25 1987-04-22 Un virus herpes simplex recombinante, vacunas y metodos. Expired - Lifetime ES2059370T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/856,052 US4859587A (en) 1984-06-04 1986-04-25 Recombinant herpes simplex viruses, vaccines and methods

Publications (1)

Publication Number Publication Date
ES2059370T3 true ES2059370T3 (es) 1994-11-16

Family

ID=25322756

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87303512T Expired - Lifetime ES2059370T3 (es) 1986-04-25 1987-04-22 Un virus herpes simplex recombinante, vacunas y metodos.

Country Status (9)

Country Link
US (1) US4859587A (es)
EP (1) EP0243155B1 (es)
JP (1) JPH084497B2 (es)
AT (1) ATE92531T1 (es)
AU (1) AU585126B2 (es)
CA (1) CA1305081C (es)
DE (1) DE3786824T2 (es)
ES (1) ES2059370T3 (es)
ZA (1) ZA87818B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5965138A (en) * 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
IL86180A (en) * 1987-05-04 1992-08-18 Merck & Co Inc Stable lyophilized live herpes virus vaccine and such a vaccine combined with other virus vaccines
US5633152A (en) * 1988-06-24 1997-05-27 Carnegie Institution Of Washington Method of controlling viral growth
GB8918616D0 (en) * 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
ES2070997T3 (es) * 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
CA2088600C (en) * 1990-08-02 1999-11-16 Rae L. Burke Herpes simplex virus vp16 vaccines
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5849572A (en) * 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US6022726A (en) * 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
US5672349A (en) * 1992-02-03 1997-09-30 Cedars Sinai Medical Center Process for the expression of herpes simplex virus type 1 glycoprotein I and methods of use
US6193984B1 (en) 1992-02-03 2001-02-27 Cedars-Sinai Medical Center Pharmaceutical composition of herpes simplex virus typ-1 (HSV-1) glycoproteins
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
CA2090295A1 (en) * 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
CA2132976C (en) 1992-03-31 2003-12-30 Bernard Roizman Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis)
US6316243B1 (en) 1992-04-14 2001-11-13 Peter Palese Genetically engineered attenuated double-stranded RNA viruses
US6183753B1 (en) * 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
TW289731B (es) * 1992-07-09 1996-11-01 Akzo Nv
WO1994003207A1 (en) * 1992-07-31 1994-02-17 President And Fellows Of Harvard College Herpesvirus vaccines
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
EP0675962B1 (en) * 1992-12-23 2003-02-05 Arch Development Corporation Synthetic herpes simplex virus promoters
CA2158935A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2728795B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
KR100408817B1 (ko) * 1995-07-28 2004-02-25 주식회사 엘지생명과학 헤르페스심플렉스바이러스의당단백질을대량발현시키는동물세포주
US5834216A (en) * 1995-09-06 1998-11-10 Arch Development Corporation Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis)
EP1314430A1 (en) * 1996-01-25 2003-05-28 The University Court Of The University Of Glasgow Treatment of non-neuronal cancer using HSV mutant
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
CA2306443A1 (en) 1997-10-14 1999-04-22 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
US6399354B1 (en) 1998-07-31 2002-06-04 President And Fellows Of Harvard College Replication-competent virus expressing a detectable fusion protein
CN1348463A (zh) * 1998-08-07 2002-05-08 华盛顿大学 免疫学单纯疱疹病毒抗原及其使用方法
JP2003535565A (ja) * 1998-12-31 2003-12-02 アーチ ディベロプメント コーポレイション 新生物疾患の治療に有用な組換え単純ヘルペスウイルス
EP1150696B1 (en) * 1999-02-05 2006-05-10 Arch Development Corporation Genetically engineered herpes virus for the treatment of tumours
US6774119B1 (en) 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
DE60034564T2 (de) 1999-07-07 2007-12-27 Zymogenetics, Inc., Seattle Menschlicher cytokinrezeptor
JP2003512305A (ja) 1999-09-30 2003-04-02 ユニバーシティ オブ ワシントン 免疫学的に重要な単純疱疹ウイルス抗原
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6516246B2 (en) * 2000-09-11 2003-02-04 Mimicking Man Manually, Inc. Method and system for determining native neurological dominant hemisphere
EP1356071B1 (en) 2000-11-28 2007-11-21 The University of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
CA2454750C (en) * 2001-07-31 2012-09-18 David M. Koelle Immunologically significant herpes simplex virus antigens and methods for using same
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
RU2225223C1 (ru) * 2002-06-14 2004-03-10 Закрытое акционерное общество Фирма "ВИТАФАРМА" Лиофилизированная антигерпетическая вакцина
DE60324678D1 (de) 2002-07-18 2008-12-24 Univ Washington N t-lymphozyten und damit identifizierte hsv-antigene
US20050069929A1 (en) 2003-08-08 2005-03-31 Invitrogen Corporation Methods and compositions for seamless cloning of nucleic acid molecules
DE602004027538D1 (de) 2003-12-01 2010-07-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20100008944A1 (en) * 2005-07-29 2010-01-14 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2413950A4 (en) 2009-04-03 2013-05-01 Univ Washington ANTIGENIC HSV-2 PEPTIDE AND METHOD OF USE THEREOF
DK2751279T3 (da) 2011-08-31 2017-11-20 St Jude Children's Res Hospital Fremgangsmåder og sammensætninger til påvisning af niveauet af lysosomal exocytose-aktivitet og fremgangsmåder til anvendelse
KR20150023287A (ko) 2012-04-24 2015-03-05 더 유니버시티 오브 마이애미 침습성 및 다중약물 내성 병원체에 대한 퍼포린 2 방어
AU2014331938A1 (en) 2013-10-09 2016-04-28 University Of Miami Perforin-2 activators and inhibitors as drug targets for infectious disease and gut inflammation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074808A3 (en) * 1981-09-16 1984-07-04 University Patents, Inc. Recombinant method and materials
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4554159A (en) * 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GB8305323D0 (en) * 1983-02-25 1983-03-30 Baylor College Medicine Infectious bovine rhinotracheitis vaccine
EP0133063B1 (en) * 1983-06-23 1987-01-07 Stanley Dr. Person Immunologically reactive non-glycosylated amino acid chains of glycoprotein b of herpes virus types 1 and 2
NL8303501A (nl) * 1983-10-12 1985-05-01 Centraal Diergeneeskundig Inst Deletiemutant van een herpesvirus en vaccin, dat dit virus bevat.
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
AU623333B2 (en) * 1986-01-27 1992-05-14 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same

Also Published As

Publication number Publication date
EP0243155A2 (en) 1987-10-28
AU6861487A (en) 1987-10-29
JPS62257385A (ja) 1987-11-09
DE3786824T2 (de) 1994-01-20
US4859587A (en) 1989-08-22
ATE92531T1 (de) 1993-08-15
DE3786824D1 (de) 1993-09-09
ZA87818B (en) 1987-12-30
JPH084497B2 (ja) 1996-01-24
CA1305081C (en) 1992-07-14
EP0243155B1 (en) 1993-08-04
AU585126B2 (en) 1989-06-08
EP0243155A3 (en) 1989-07-26

Similar Documents

Publication Publication Date Title
AU585126B2 (en) Recombinant herpes simplex viruses, vaccines and methods
ES2150416T3 (es) Vacuna virica defectiva producida por una linea celular complementada en trans.
DE69125925D1 (de) Rekombinante herpes simplex virus impfstoffe und methoden
AR025502A1 (es) Composicion de vacuna adecuada para usar en el tratamiento o la profilaxis de infecciones de virus del papiloma humano e infecciones de virus del herpes simple.
ES2070997T3 (es) Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
ES2035818T3 (es) Mutantes de delecion de la timidin-kinasa del virus del herpes bovino-1, vacunas contra la rinotraqueitis bovina infecciosa que los contienen y metodos para su produccion y uso.
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
EE05138B1 (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
BR9908599A (pt) Composições combinadas de vacina
MY110086A (en) Herpes simplex virus vaccines comrpising glycoprotein d and 3d-mpl
CY1110359T1 (el) Εμβολια με βαση σιρκοϊους χοιρων
CA2243570A1 (en) Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
PE84699A1 (es) Formula de vacuna polinucleotidica especialmente contra la patologia respiratoria de los bovinos
EP0261940A3 (en) Pseudorabies vaccines and dna vectors for recombination with pox viruses
ES2066842T3 (es) Virus recombinante de la enfermedad de marek y vacuna.
EP0175787A4 (en) RECOMBINANT gB-gD VACCINE AGAINST HERPES SIMPLEX.
EA200300215A1 (ru) Вакцинация против вирусов герпеса, ассоциированных с хозяйской клеткой
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
ES2188589T3 (es) Vacuna recombinante del herpes virus felino.
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
ES2053477T3 (es) Vacuna viva para enfermedades contagiosas de pollos.
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
ES2054230T3 (es) Un proceso para la preparacion de un enterovirus o rinovirus atenuado.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 243155

Country of ref document: ES